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Original Investigation | Geriatrics

Assessment of Plasma Amyloid-β42/40 and Cognitive Decline
Among Community-Dwelling Older Adults
Kelly Virecoulon Giudici, PhD; Philipe de Souto Barreto, PhD; Sophie Guyonnet, PhD; Yan Li, PhD; Randall John Bateman, MD; Bruno Vellas, MD, PhD;
for the MAPT/DSA Group

Abstract
IMPORTANCE Plasma measurement of amyloid-β (Aβ) peptides has been associated with cognitive
function, but evidence of its ability to identify cognitive decline is still scarce.
OBJECTIVE To investigate the associations between plasma Aβ42/40 and cognitive decline over time
among community-dwelling older adults with subjective memory concerns.

Key Points
Question Is plasma amyloid-β42/40
(Aβ42/40) associated with cognitive
decline among community-dwelling
older adults with memory concerns?
Findings In this cohort study of 483
participants from a randomized clinical

DESIGN, SETTING, AND PARTICIPANTS This multicenter cohort study used data from volunteers

trial, low plasma Aβ42/40 ratio was

in the 5-year study Multidomain Alzheimer Preventive Trial (MAPT). Participants were aged 70 years

significantly associated with more

or older and observed for a median (interquartile range) of 3.9 (2.0-4.0) years. Recruitment of

pronounced decline in composite

participants started in May 2008 and ended in February 2011. Follow-up ended in April 2016. Data

cognitive score and Mini Mental State

analysis was conducted from April to October 2020.

Examination score over time.
Meaning In this study, low plasma

EXPOSURE Plasma Aβ42 and Aβ40 were measured at 12 months for 448 participants (92.8%) and
at 24 months for the rest. The moment of Aβ assessment was defined as the baseline for this study.

Aβ42/40 was associated with more
pronounced decline in cognitive
function over time, suggesting that this

MAIN OUTCOMES AND MEASURES Cognitive function was assessed at 12, 24, 36, 48, and 60
months by a composite cognitive score based on 4 tests; Mini Mental State Examination (MMSE);
Clinical Dementia Rating, sum of boxes; and Alzheimer Disease Cooperative Study–Activities of Daily
Living. Mixed-effect linear regressions were performed.
RESULTS A total of 483 participants (median [IQR] age, 76.0 [73.0-80.0]; 286 [59.2%] women)
were analyzed. Of them, 161 (33.3%) were classified as low plasma Aβ42/40 (ⱕ0.107). After adjusting
for age, sex, education, body mass index, Geriatric Depression Scale score, apolipoprotein E ε4
genotype, and MAPT intervention groups, low plasma Aβ42/40 was associated with more

marker may be used to identify people
at risk of cognitive decline and as an
alternative to more complex and
expensive measures.

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

pronounced decline in composite cognitive score (adjusted between-group mean difference: −0.20,
95% CI, −0.34 to −0.07; P = .004) and decline in MMSE score (adjusted between-group mean
difference: −0.59; 95% CI, −1.07 to −0.11; P = .02) during the follow-up period compared with the
group with an Aβ42/40 ratio greater than 0.107.
CONCLUSIONS AND RELEVANCE In this study, low plasma Aβ42/40 was associated with more
pronounced decline in cognitive function (measured by multiple outcomes) over time. Findings
suggest that plasma Aβ42/40 may be used to identify people at risk of cognitive decline, being an
alternative to more complex and expensive measures, such as positron emission tomography
imaging or cerebrospinal fluid measurement.
JAMA Network Open. 2020;3(12):e2028634. doi:10.1001/jamanetworkopen.2020.28634
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Introduction
Brain accumulation of amyloid-β (Aβ) peptides is known to be intimately associated with the
physiological landscape of Alzheimer disease (AD).1 Measures of Aβ have been used as an early
marker of cognitive impairment and AD, assessed by positron emission tomography (PET) imaging or
measurement in cerebrospinal fluid (CSF).1 In a search for less expensive, minimally invasive, and fast
and reliable markers, plasma measures of Aβ have recently emerged as a potential equivalent to PET
imaging and CSF measurements in determining Aβ status.2-5 Early attempts to measure Aβ in plasma
presented limited utility for diagnosis or prognosis of cognitive impairment and AD due to high
variability attributed to a lack of high precision methods of assessment in plasma samples.5-7 More
recently, a high-precision immunoprecipitation and liquid chromatography–mass spectrometry assay
has provided reliable measures of plasma Aβ peptides,2,3,8-11 but investigations associating this
marker with clinical cognitive outcomes are scarce.
The association between plasma Aβ and cognitive function has been previously shown in
cross-sectional12 and longitudinal analyses13-16; however, such publications from approximately a
decade ago provided low accuracy for plasma Aβ measures at the individual level. Studies exploring
cognitive associations with longitudinal cohorts of older adults by using highly reliable techniques are
still scarce and present multiple methodological differences that prevented reaching a
consensus.17-20 Further studies are needed to confirm the use of high-accuracy plasma Aβ in
associating Aβ levels with cognitive decline to determine the usefulness of this marker in clinical care
and research.
This study aimed to investigate the associations between plasma Aβ42/40 and cognitive decline
over time among community-dwelling older adults with spontaneous memory concerns. We
hypothesized that Aβ42/40 status may be associated with changes in cognitive function over time
among community-dwelling older adults, with lower Aβ ratio associated with more pronounced
cognitive decline.

Methods
Study Design and Population
This cohort study uses data from participants from the Multidomain Alzheimer Preventive Trial
(MAPT), a randomized, multicenter, placebo-controlled trial conducted with community-dwelling
older adults in France and Monaco. Participants were allocated into 4 groups, either receiving ω-3
polyunsaturated fatty acid (PUFA) supplementation, a multidomain intervention (based on cognitive
training, nutritional counseling, and physical activity advice), both, or none (in this case, taking
placebo capsules). The intervention phase lasted for 3 years and was then followed by an additional
2-year observational phase (without any intervention). Recruitment of participants started in May
2008 and ended in February 2011. Follow-up ended in April 2016.
Complete inclusion and exclusion criteria as well as other details about the MAPT protocol, can
be found elsewhere.21,22 In summary, inclusion criteria comprised age 70 years or older; not
presenting major neurocognitive disorders (Mini-Mental State Examination [MMSE] score, ⱖ24);
presenting at least 1 of the following: spontaneous memory concern, inability to perform 1
instrumental activity of daily living (ADL), or slow walking speed (<0.8 m/s in a 4-m usual walking
test). Participants were not included if they declared the use of ω-3 PUFA supplements during the 6
months prior to inclusion. From the 1680 individuals originally included in MAPT, 483 with available
blood samples had their plasma Aβ measured and were thus included in the present study (Figure 1).
A comparison of baseline characteristics between MAPT participants enrolled in the present study
and those who were not included is shown in eTable 1 in the Supplement.
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Ethical Disclosure
Eligible subjects provided written informed consent after accepting to join the investigation. The
MAPT Study (trial protocol NCT00672685) was authorized by the French Health Authority and
approved by the Advisory Committee for the Protection of Persons participating in Biomedical Research
of Toulouse. The present study followed the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) reporting guideline.23

Aβ Status
Plasma Aβ42 and Aβ40 were measured at 12 months for 448 participants (92.8%) and at 24 months
for 35 (7.2%) (due to unavailability of samples at baseline and 12 months). Plasma samples were
spiked with a known quantity of 12C15N-Aβ42 and 12C15N-Aβ40 for use as analytical internal
standards. A full description of the immunoprecipitation methods applied has been previously
described.11 Briefly, Aβ42 and Aβ40 isoforms were simultaneously immunoprecipitated from 0.45 mL
of plasma via a monoclonal anti-Aβ middomain antibody (HJ5.1, anti-Aβ13-28) conjugated to M-270
Epoxy Dynabeads (Invitrogen). Protein digestion into peptides was done using LysN endoprotease
(Pierce). Liquid chromatography–mass spectrometry was performed as detailed elsewhere.11 Plasma
analyses were performed as targeted parallel reaction monitoring on an Orbitrap Fusion Lumos
Tribrid mass spectrometer (Thermo Fisher) interfaced with an M-class nanoAcquity chromatography
system (Waters). The precursor and product ion pairs used for analysis of Aβ isoforms were chosen
as previously detailed.2,24 Derived integrated peak areas were analyzed using the Skyline software
package.25 Aβ42 and Aβ40 quantities (in picograms per milliliter) were calculated by integrated peak
area ratios to known concentrations of the internal standards. The plasma Aβ42/40 ratio was then
calculated by dividing Aβ42 by Aβ40, and its normalized values were used to classify Aβ status
(determined by Youden index as low if ⱕ0.107 and normal if >0.107, using amyloid PET status as the
reference standard).

Figure 1. Flow Diagram Describing the Population of the Study
2591 Assessed for eligibility

911 Excluded
135 Did not meet inclusion criteria
682 Declined to participate
39 Did not attend the baseline visit
55 Screened just before the end
of inclusion period

1680 Randomized

417 Randomized to multidomain
intervention with omega-3
supplementation
305 Not analyzed
288 Did not undergo
assessment of
plasma Aβ
17 Did not finish the study
3 Died
5 Refused to continue
3 Lost to follow-up
5 Adverse events
1 Had other reasons

129 Analyzed

423 Randomized to omega-3
supplementation

329 Not analyzed
311 Did not undergo
assessment of
plasma Aβ
18 Did not finish the study
3 Died
8 Refused to continue
2 Lost to follow-up
4 Adverse events
1 Had other reasons

112 Analyzed

420 Randomized to multidomain
intervention with placebo

325 Not analyzed
300 Did not undergo
assessment of
plasma Aβ
25 Did not finish the study
2 Died
8 Refused to continue
10 Lost to follow-up
4 Adverse events
1 Had other reasons

120 Analyzed

423 Randomized to placebo

319 Not analyzed
301 Did not undergo
assessment of
plasma Aβ
18 Did not finish the study
3 Died
10 Refused to continue
2 Lost to follow-up
3 Adverse events

122 Analyzed

Aβ indicates amyloid-β.
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Outcomes
Outcomes were measured annually and comprised a composite cognitive score based on 4 tests; the
MMSE score; the Clinical Dementia Rating (CDR) sum of boxes; and the Alzheimer Disease
Cooperative Study–ADL (ADCS-ADL) score. The composite cognitive score (whose higher values
mean better cognitive function) was composed of the mean value of 4 z scores, given by the 10
orientation items of the MMSE, the Digit Symbol Substitution Test, free and total recall of the Free
and Cued Selective Reminding test, and the Category Naming Test.22 The MMSE score ranges from 0
to 30, with higher scores indicating better function.26 The CDR sum of boxes evaluates 6 domains
(memory; orientation; judgement and problem solving; community affairs; home and hobbies; and
personal care), which are scored individually from 0 to 3 (thus achieving a maximum score of 18, with
higher scores indicating worse function).27 Finally, the ADCS-ADL scale ranges from 0 to 45, with
higher scores indicating better function.28

Potential Confounders
Potential confounders consisted of age (continuous variable), sex (male vs female), education (no
diploma, primary school certificate, secondary education, high school diploma, university level),
body mass index (BMI; calculated as weight in kilograms divided by height in meters squared),
allocation to MAPT groups (multidomain intervention with ω-3 supplementation; multidomain
intervention with placebo; ω-3 supplementation alone; and placebo alone), CDR status at baseline
(CDR score 0, 0.5, or ⱖ1), Geriatric Depression Scale (GDS) score (continuous), and apolipoprotein E
(APOE) ε4 genotype (carrier vs noncarrier).

Statistical Analysis
Descriptive statistics (medians and interquartile ranges [IQRs] or frequencies and percentages, as
appropriate) were used for characterization of the study population. The moment in which
participants had their plasma Aβ measured was considered the baseline (ie, either 12 or 24 months,
as appropriate); no outcome data obtained before Aβ measurement were used. Quantitative
variables at baseline were compared according to Aβ status by Wilcoxon-Mann-Whitney test, and
categorical variables were compared using the χ2 test.
Linear mixed-effects regression analyses were performed to determine associations between
plasma Aβ status (independent variable) and changes in outcomes (dependent variables) over time,
with adjustments for potential confounders (model 1: sex, age, education, BMI, MAPT group, CDR
status at baseline, GDS score, and APOE ε4 genotype; model 2: all confounders except APOE ε4
genotype). A Cramer V of −0.20 indicated weak collinearity between APOE ε4 genotype and Aβ
status. CDR status at baseline was not included when the outcome was CDR sum of boxes. In the
absence of an agreed-upon range in literature to determine plasma Aβ status, sensitivity analyses
using the 25th percentile of Aβ42/40 as an alternative cutoff were performed (low Aβ, ⱕ0.103). In
addition, to rule out the potential effects of MAPT interventions on both Aβ and cognitive outcomes,
sensitivity analyses using the cutoff of 0.107 but restricted to the placebo group (n = 122) were done.
Sensitivity analyses were also performed with plasma Aβ as a continuous variable, including the same
potential confounders as the models reported earlier. For these analyses, 1 participant was excluded
due to presenting extremely high value of Aβ42/40 (>12 SDs above the mean value).
Cox proportional hazard models were performed to explore associations between plasma
Aβ42/40 and worsening CDR status among participants with CDR scores of less than 1 at baseline,
considering the same models of adjustment already described. Time to first event was determined as
the time interval for changing from cognitively normal (CDR score, 0) at baseline to mild cognitive
impairment (MCI; CDR score, 0.5) or changing from MCI at baseline to major cognitive impairment
(CDR score, ⱖ1). Participants without the event were censored at their last CDR assessment visit.
Proportional hazard assumption was tested using the Kolmogorov-type supremum test, and P > .05
was considered nonviolation of the assumption. Analyses were performed with the SAS version 9.4
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(SAS Institute), at a significance level of P < .05 with 2-tailed tests. Data analysis was conducted from
April to October 2020.

Results
Characterization of the Sample
From the 483 participants of the study (median [IQR] age, 76.0 [73.0-80.0] years), 286 (59.2%)
were women and 128 (26.9%) had a university-level education. As presented in Table 1, 161
participants (33.3%) were classified as having low plasma Aβ42/40 (ⱕ0.107; hereafter, Aβ+). The Aβ+
group, compared with participants in the Aβ– group (ie, those with Aβ42/40 >0.107), was older
(median [IQR] age, 77.0 [73.0-80.0] years vs 76.0 [73.0-80.0] years; P = .02) and included more
men (80 [49.7%] vs 117 [36.3%]; P = .005) and more APOE ε4 carriers (60 [40.3%] vs 61 [21.1%];
P < .001). Median (IQR) follow-up was 3.9 (2.0-4.0) years.

Changes in Outcomes Over Time According to Plasma Aβ Status
During follow-up, both groups experienced significant decrease in composite cognitive score and
increase in CDR sum of boxes. Cognitive decline according to the composite cognitive score was
more pronounced in the Aβ+ group than in the Aβ– group (adjusted between-group mean difference:
−0.20, 95% CI, −0.34 to −0.07; P = .004) (Table 2). In the same period, MMSE score significantly
decreased in the Aβ+ group and remained stable among Aβ– participants, with a significant
difference between groups (adjusted between-group mean difference: −0.59; 95% CI, −1.07 to −0.11;
P = .02). Both groups presented significant decreases in ADCS-ADL score over time, but there was

Table 1. Characteristics of the Sample According to Plasma Aβ42/40 Status
Median (IQR)
Characteristics

Participants,
No.

Total
(N = 483)

Low plasma Aβ42/40
(n = 161)a

Normal plasma
Aβ42/40 (n = 322)

Women, No. (%)

483

286 (59.2)

81 (50.3)

205 (63.7)b

Age, y

483

76.0 (73.0-80.0)

77.0 (73.0-80.0)

76.0 (73.0-80.0)b

Education, No. (%)
No diploma

22 (4.6)

6 (3.8)

16 (5.1)

Primary school certificate

99 (20.8)

39 (24.5)

60 (18.9)

Secondary education

476

High school diploma
University level

158 (33.2)

61 (38.4)

97 (30.6)

69 (14.5)

16 (10.1)

53 (16.7)

128 (26.9)

37 (23.3)

91 (28.7)

Weight, kg

480

69.3 (61.0-79.0)

70.0 (61.0-79.0)

69.0 (61.0-79.0)

Body mass indexc

480

26.0 (23.6-28.7)

25.8 (23.9-28.2)

26.2 (23.5-28.8)

Plasma amyloid-β42/40 ratio

483

0.113
(0.103-0.123)

0.099
(0.093-0.103)

0.119
(0.113-0.127)b

Composite cognitive scored

478

0.16 (−0.28 to 0.55)

0.10 (−0.45 to 0.53)

0.17 (−0.25 to 0.56)

CDR sum of boxes, range 0-18

481

0.5 (0 to 0.5)

0.5 (0 to 0.5)

0.5 (0 to 0.5)

CDR status, No. (%)
No cognitive impairment,
CDR score, 0
Mild cognitive impairment,
CDR score, 0.5

481

Major cognitive impairment,
CDR score, ≥1

212 (43.9)

64 (39.8)

148 (46.0)

268 (55.5)

96 (59.6)

172 (53.4)

3 (0.6)

1 (0.6)

2 (0.6)

MMSE score, range 0-30

481

28 (27-29)

28 (26-29)

28 (27-29)

ADCS-ADL score, range 0-45

473

41 (37-44)

41 (37-43)

41 (37-44)

Geriatric Depression scale,
range 0-15

479

2 (1-4)

3 (1-4)

2 (1-5)

APOE ε4 genotype, No. (%)
APOE ε4 carriers
Non-APOE ε4 carriers

438

b

121 (27.6)

60 (40.3)

61 (21.1)

317 (72.4)

89 (59.7)

228 (78.9)
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a

Low Aβ42/40 defined as 0.107 or less.

b

P < .05 based on Wilcoxon-Mann-Whitney test or
Pearson χ2 test.

c

Body mass index calculated as weight in kilograms
divided by height in meters squared.

d

Based on the z score of 4 cognitive tests (free and
total recall of the Free and Cued Selective Reminding
test, 10 MMSE orientation items, Digit Symbol
Substitution Test, and Category Naming Test).
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no significant between-group difference (Table 2 and Figure 2). Adjusted models not including APOE
ε4 as a potential confounder provided similar findings (eTable 2 in the Supplement).
From the 212 participants who had CDR scores of 0 at blood assessment and had at least 1 other
longitudinal measure of CDR score, 141 (66.5%) evolved to MCI. From the 268 participants who had
MCI (CDR score, 0.5) at blood assessment and had at least 1 other longitudinal measure of CDR score,
19 (7.1%) evolved to major cognitive impairment during follow-up. Frequency of events was,
therefore, 160 of 459 (34.9%). Participants in the Aβ+ group (according to the main cutoff of 0.107)
did not present a significantly higher hazard of CDR worsening, compared with those in the Aβ–
group (Table 3).

Sensitivity Analyses With Lowest Aβ42/40 Quartile as Cutoff
Using the lowest quartile to classify Aβ status resulted in 120 participants (24.8%) categorized as Aβ+
(Aβ42/40, ⱕ0.103). This group, compared with participants with Aβ42/40 greater than 0.103, was
older (median [IQR] 77.0 [73.0-80.5] years vs 76.0 [73.0-80.0] years; P = .02) and included fewer
women (57 [47.5%] vs 229 [63.1%]; P = .003) and more APOE ε4 carriers (48 [41.7%] vs 73 [22.6%];
P < .001). Analyses of the evolution of outcomes over time according to this alternative classification
are shown in eTable 3 in the Supplement. Findings were similar to those presented with the original
cutoff: participants in the Aβ+ group presented a more pronounced decline in composite cognitive
score; MMSE only declined among the Aβ+ group. In addition, a more pronounced increase in CDR
Table 2. Mixed-Effect Linear Regression Analysis for Variation in Outcomes Over Time According to Plasma Amyloid-β42/40 Status
Among Community-Dwelling Older Adults
Low plasma amyloid-β42/40a
Period

d

Estimated mean (95% CI)

Normal plasma amyloid-β42/40
d

Unadjusted modelb

Adjusted modelc

P value Estimated mean (95% CI)

P value Differences (95% CI)

P value

Differences (95% CI)

P value

Composite cognitive scoree
24 mo (1-y change)

−0.25 (−0.33 to −0.16)

<.001

−0.12 (−0.19 to −0.06)

<.001

−0.12 (−0.23 to −0.02)

.03

−0.12 (−0.23 to 0.00)

.04

36 mo (2-y change)

−0.35 (−0.44 to −0.26)

<.001

−0.16 (−0.22 to −0.09)

<.001

−0.19 (−0.30 to −0.08)

.001

−0.19 (−0.30 to −0.07)

.002

48 mo (3-y change)

−0.38 (−0.48 to −0.28)

<.001

−0.19 (−0.26 to −0.12)

<.001

−0.19 (−0.31 to −0.07)

.002

−0.18 (−0.32 to −0.05)

.01

60 mo (4-y change)

−0.45 (−0.56 to −0.35)

<.001

−0.26 (−0.33 to −0.19)

<.001

−0.20 (−0.32 to −0.07)

.002

−0.20 (−0.34 to −0.07)

.004

CDR sum of boxes, range 0-18
24 mo (1-y change)

0.26 (0.10 to 0.41)

.002

0.08 (−0.04 to 0.19)

.18

0.18 (−0.02 to 0.37)

.07

0.11 (−0.08 to 0.30)

.24

36 mo (2-y change)

0.31 (0.15 to 0.48)

<.001

0.12 (0.01 to 0.24)

.04

0.19 (−0.01 to 0.39)

.06

0.18 (−0.02 to 0.38)

.08

48 mo (3-y change)

0.29 (0.10 to 0.47)

.002

0.10 (−0.02 to 0.22)

.11

0.19 (−0.04 to 0.41)

.10

0.12 (−0.11 to 0.34)

.30

60 mo (4-y change)

0.43 (0.24 to 0.62)

<.001

0.29 (0.16 to 0.41)

<.001

0.15 (−0.08 to 0.37)

.21

0.22 (0.01 to 0.44)

.06

24 mo (1-y change)

−0.47 (−0.78 to −0.16)

.003

0.03 (−0.20 to 0.25)

.82

−0.50 (−0.88 to −0.11)

.01

−0.42 (−0.82 to −0.02)

.04

36 mo (2-y change)

−0.69 (−1.01 to −0.36)

<.001

−0.11 (−0.34 to 0.12)

.34

−0.57 (−0.97 to −0.18)

.004

−0.54 (−0.96 to −0.12)

.01

48 mo (3-y change)

−0.37 (−0.74 to −0.01)

.005

−0.01 (−0.25 to 0.23)

.94

−0.36 (−0.80 to 0.07)

.10

−0.30 (−0.78 to 0.18)

.22

60 mo (4-y change)

−0.72 (−1.10 to −0.35)

<.001

−0.16 (−0.41 to 0.08)

.20

−0.56 (−1.01 to −0.11)

.01

−0.59 (−1.07 to −0.11)

.02

.29

MMSE score, range 0–30

ADCS-ADL score, range 0-45
24 mo (1-y change)

−1.39 (−2.16 to −0.62)

<.001

−0.50 (−1.05 to 0.06)

.08

−0.89 (−1.84 to 0.06)

.06

−0.54 (−1.53 to 0.45)

36 mo (2-y change)

−1.28 (−2.09 to −0.48)

.002

−0.22 (−0.78 to 0.35)

.46

−1.07 (−2.05 to −0.08)

.03

−0.95 (−1.98 to 0.09)

.07

48 mo (3-y change)

−1.99 (−2.90 to −1.07)

<.001

−0.61 (−1.21 to −0.01)

.05

−1.37 (−2.47 to −0.28)

.01

−0.92 (−2.11 to 0.27)

.13

60 mo (4-y change)

−1.73 (−2.67 to −0.78)

<.001

−0.85 (−1.46 to −0.24)

.006

−0.88 (−2.00 to 0.25)

.13

−0.34 (−1.54 to 0.86)

.58

35 [7.2%]). Negative values for within-group differences mean cognitive decline,
except for CDR sum of boxes (for which it is given by positive values). Positive values
for between-group differences indicate more pronounced cognitive decline among the
low plasma Aβ42/40 group, except for CDR sum of boxes (for which it is given by
negative values).

Abbreviations: ADCS-ADL, Alzheimer Disease Cooperative Study–Activities of Daily
Living; CDR, Clinical Dementia Rating; MMSE, Mini-Mental State Examination.
a

Low Aβ42/40 defined as 0.107 or less.

b

Included 481 participants.

c

Included 433 participants. Model was adjusted by age, sex, education, body mass
index, apolipoprotein E ε4 genotype, Geriatric Depression Scale score, MAPT
intervention group, and CDR status at baseline (except for the analysis with CDR sum
of boxes).

d

e

Based on the z score of 4 cognitive tests (free and total recall of the Free and Cued
Selective Reminding test; 10 MMSE orientation items; Digit Symbol Substitution Test;
and Category Naming Test).

Outcome evolution was compared considering the moment when plasma amyloid-β
was measured as baseline (12 months for 448 participants [92.8%] and 24 months for
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sum of boxes was observed in this group. Cox analysis using the alternative cutoff of 0.103 for Aβ
status found no difference in hazard of CDR worsening among participants in Aβ+ and Aβ– groups
(Table 3).

Sensitivity Analysis: Restricted to the MAPT Control Group
When analyzing only participants who did not receive any intervention in the MAPT study
(decreasing sample to 122 participants, suggesting reduced power) and using the cutoff of 0.107, 50
participants (41.0%) were considered Aβ+. This group presented no differences in descriptive
characteristics compared with participants in the Aβ– group. Results given by mixed models
remained similar for MMSE score, with participants in the Aβ+ group declining and participants in the
Aβ– group remaining stable over time. Both groups (Aβ+ and Aβ–) presented within-group significant
decline in composite cognitive score and ADCS-ADL score over time, but there was no significant
between-group difference. CDR sum of boxes only worsened among the Aβ+ group, with no
significant adjusted between-group mean difference (eTable 4 in the Supplement).

Figure 2. Variation in Outcomes Over Time According to Plasma Amyloid-β42/40 Status Among Community-Dwelling Older Adults
A Composite cognitive score

B
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ADCS-ADL indicates Alzheimer Disease Cooperative Study–Activities of Daily Living.
a

P < .05 for adjusted between-group difference according to the cutoff of 0.107.

b

P < .05 for adjusted between-group difference according to the cutoff of 0.103.

Participants, No.
438

308
c

440

404

P < .05 for adjusted between-group difference according to the cutoffs of 0.107
and 0.103.
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Sensitivity Analysis With Plasma Aβ42/40 as a Continuous Variable
Analyzed as a continuous variable, plasma Aβ42/40 was positively associated with the composite
cognitive score during follow-up, indicating that participants with lower plasma Aβ42/40 had a more
pronounced decline in composite cognitive score over time (adjusted β = 5.51; 95% CI, 1.35 to 9.67;
P = .009), but results were not statistically significant after additionally adjusting for APOE ε4
genotype (β = 4.22; 95% CI, −0.17 to 8.62; P = .06). Significant associations were also observed for
MMSE score in the adjusted model not including APOE ε4 genotype (adjusted β = 18.32; 95% CI,
3.44 to 33.20; P = .02). However, no significant associations were observed for all outcomes at the
end of follow-up in the model additionally adjusted for APOE ε4 genotype (eTable 5 in the
Supplement).

Discussion
This study investigated the association between plasma Aβ42/40 status and cognitive decline among
community-dwelling older adults and found that low plasma Aβ42/40 was associated with more
pronounced decline in cognitive function during a median follow-up of 3.9 years. However, this
biomarker was not associated with changes in ADCS-ADL score. Results were confirmed with an
alternative cutoff. Sensitivity analysis restricted to the control group of MAPT Study confirmed the
main findings for MMSE score.
These important findings are in line with previous investigations on the topic. The first
longitudinal studies exploring plasma Aβ measures and outcomes of cognitive function among older
adults associated low plasma Aβ42/40 with greater risk of MCI or AD after a median follow-up of 3.7
years13 and with more pronounced cognitive decline over 9 years.16 Accordingly, high plasma Aβ40/42
(the inverse ratio) was associated with more pronounced decline in global cognition during a 10-year
period among older women volunteers from the Nurses’ Health Study.14 In contrast, high baseline
plasma Aβ42 and Aβ40 values were associated with faster decline in multiple cognitive domains
among a sample of older adults followed for approximately 4.5 years.15 However, not all studies were
able to identify longitudinal associations between plasma Aβ and cognitive decline or conversion to
MCI and AD.29,30 Comparisons of the current findings with older publications should nevertheless be
cautious, given that the lack of sensitive and accurate analytical methods precluded high individual
accuracy and achieving consistent and reliable evidence with the prior assay measurements.
More recently, the association between plasma Aβ and clinical cognitive outcomes has been
explored with improved techniques for assessing plasma Aβ in some cross-sectional studies, which
identified mixed findings among older adults.31-33 Highlighting the need for determining early
predictors of cognitive impairment, it is imperative to explore such associations longitudinally, as we

Table 3. Cox Proportional Hazard Models for Clinical Dementia Rating Worsening According to Plasma Aβ42/40 Status During Follow-up Perioda
Adjusted
Model 1 (n = 410)b

Unadjusted model (n = 459)
Group

HR (95% CI)

P value

HR (95% CI)

Model 2 (n = 450)c
P value

HR (95% CI)

P value

Predefined cutoff
Normal plasma Aβ42/40 (>0.107)

1 [Reference]

NA

1 [Reference]

NA

1 [Reference]

NA

Low Aβ42/40 (≤0.107)

1.09 (0.79-1.52)

.60

1.03 (0.71-1.49)

.89

1.02 (0.72-1.44)

.91

Alternative cutoff, ie, lowest quartile
Normal plasma Aβ42/40 (>0.103)

1 [Reference]

NA

1 [Reference]

NA

1 [Reference]

NA

Low Aβ42/40 (≤0.103)

1.36 (0.97-1.92)

.08

0.97 (0.67-1.42)

.89

0.98 (0.69-1.39)

.91

Abbreviation: HR, hazard ratio; NA, not applicable.
a

CDR worsening was defined as changing from cognitively normal (CDR score, 0) at
baseline to mild cognitive impairment (CDR score, 0.5) or changing from mild cognitive
impairment at baseline to major cognitive impairment (CDR score, ⱖ1) considering the
moment when plasma Aβ was measured as the baseline (12 or 24 months).

b

Model 1 was adjusted by age, sex, education, body mass index, Geriatric Depression
Scale score, apolipoprotein E ε4 genotype, and MAPT intervention group.

c

Model 2 was adjusted by age, sex, education, body mass index, Geriatric Depression
Scale score, and MAPT intervention group.
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did in the present study. Despite the few reports focusing on cognitive outcomes and evaluating
participants with different cognitive status and age ranges, the existing evidence from recent
longitudinal studies points toward the usefulness of plasma Aβ42/40.17,18 The plasma Aβ42/40 ratio was
not investigated by Iulita et al,19 but authors found that lower plasma Aβ42 and Aβ40 alone were both
associated with a 3-year cognitive decline among a cohort of at-risk individuals and individuals
clinically diagnosed with probable AD. On the other hand, a study of patients with AD found no
association between plasma Aβ42/40 and MMSE score after a 2-year follow-up.20
Taken together, evidence from our study suggests that plasma Aβ42/40 is capable of identifying
later cognitive decline among community-dwelling older adults with spontaneous memory concerns.
Although this field is still in its beginning, our findings support the potential utility of plasma Aβ in
research (eg, for selection of at-risk individuals for clinical trials or use as a proxy end point alongside
other clinical markers). The usefulness of this biomarker in clinical care (ie, to increase diagnostic
confidence, determine therapeutic strategies, or provide additional information on the brain Aβ
deposition status of individuals) nevertheless demands further investigations.

Strengths and Limitations
This study has multiple strengths. We assessed multiple cognitive outcomes and used a recent and
improved measurement technique for plasma Aβ. Moreover, the longitudinal approach and the
relatively large sample size are additional strengths. However, there are some limitations to be
mentioned. This was a secondary analysis of a randomized clinical trial. However, the MAPT
intervention did not affect cognition,22 and allocation to intervention groups was included as a
confounder in the analyses. Plasma Aβ peptides were only assessed in a subsample of participants
from MAPT, 1 or 2 years after inclusion because baseline samples were not available. Some
characteristics of MAPT participants at inclusion were not similar between the sample of the present
study and those who were not included, what may potentially be a selection bias. As normally seen
in long follow-up studies, measures were not available to all participants at all moments. In addition,
the sensitivity analysis restricted to the control group of MAPT was performed with a smaller sample
and thus presented limited statistical power; its results should be therefore interpreted with caution.
Finally, it is worth mentioning that participants of this study presented a particularly high
educational level.

Conclusions
With life expectancy increasing worldwide, interest in identifying early markers of cognitive decline
has gained momentum, putting biomarkers with a potential to predict cognitive impairment in the
spotlight. In the present study, low plasma Aβ42/40 was longitudinally associated with more
pronounced declines in cognitive function, measured by multiple outcomes, during as long as 4 years
of follow-up among community-dwelling older adults. Following evidence from previous
publications2-5 that central and peripheral Aβ load are in dynamic balance, our findings show that
plasma Aβ42/40 may be used to identify people at risk of cognitive decline, being an alternative to
more complex and expensive measures such as PET scanning or CSF Aβ load. General cutoffs for
determining plasma Aβ status remain to be determined in future investigations. Further studies with
long follow-up periods and that target multiple cognitive measures are needed to confirm its utility
in clinical practice and public health care.
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